Akums Drugs & Pharmaceuticals Ltd. submitted its Monitoring Agency Report for the quarter ended December 31, 2025, as required for its Initial Public Offer (IPO). The report, prepared by CRISIL Ratings Limited, confirms the utilization of proceeds. All monitored objects, including debt repayment and funding working capital, were fully utilized during previous quarters. The unutilized proceeds remaining as of the reporting date amount to Rs 49.07 million, held in the public offer account.
Submission of Quarterly Monitoring Report
Akums Drugs and Pharmaceuticals Limited has formally submitted the Monitoring Agency Report concerning the utilization of proceeds from its Initial Public Offer (IPO). This submission covers the financial quarter ending December 31, 2025.
Utilization Status of IPO Proceeds
The monitoring report details the status against the objects outlined in the Offer Document. Based on the review conducted by the Monitoring Agency:
- Repayment/Prepayment of Indebtedness (Company & Subsidiaries): The planned utilization of Rs 1,599.10 million and Rs 2,270.90 million, respectively, was Fully utilized by the September 2024 and December 2024 quarters.
- Funding Incremental Working Capital: The allocated Rs 550.00 million was Fully utilized by the March 2025 quarter.
- Pursuing Inorganic Growth (Acquisitions): The projected Rs 278.70 million was Fully utilized by the June 2025 quarter.
- General Corporate Purposes (GCP): The amount utilized under GCP was Fully utilized in the December 2024 quarter.
Unutilized Proceeds Balance
As of December 31, 2025, the total unutilized net proceeds stand at Rs 6,373.70 million, reported as Fully Utilised across the specified objects, indicating that all planned expenditures from the IPO funds have been accounted for against the stated purposes.
Remaining Balance for Specific Expenses
A specific balance remains allocated for issue expenses:
- The balance in the Public Offer account pertaining to issue expenses amounts to Rs 49.07 million. The total public offer account balance was Rs 128.53 million, with the company’s share earmarked for expenses being Rs 49.07 million.
Monitoring Confirmation
The Monitoring Agency confirmed that the utilization was in line with disclosures, and there were no material deviations observed regarding utilization or changes in the means of finance for the disclosed objects during the reporting period.
Source: BSE
